Alkermes Announces Positive Results from Phase 1 Study of ALKS 3831
plc (NASDAQ: ALKS) today announced positive topline results from a
phase 1 study of its new antipsychotic candidate, ALKS 3831, a
combination of a proprietary drug molecule, ALKS 33, and olanzapine, a
molecule that is commercially available under the name ZYPREXA®.
ALKS 3831 is in development for the treatment of schizophrenia, a
central nervous system (CNS) disease, and is designed to attenuate the
antipsychotic-related metabolic side effect of weight gain.
The multicenter, randomized, double-blind, placebo- and
active-controlled study was designed to compare the mean change from
baseline in body weight in 106 healthy volunteers following three weeks
of once-daily, oral administration of ALKS 3831, compared to olanzapine